摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-羟基-6-苯基己腈 | 288863-28-5

中文名称
2-羟基-6-苯基己腈
中文别名
——
英文名称
2-hydroxy-6-phenylhexanenitrile
英文别名
——
2-羟基-6-苯基己腈化学式
CAS
288863-28-5
化学式
C12H15NO
mdl
——
分子量
189.257
InChiKey
DYLWAQBBAIIOSZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    44
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-羟基-6-苯基己腈2,6-二甲基吡啶bis(triphenylphosphine)nickel(II) chloride4,4'-二叔丁基-2,2'-二吡啶 作用下, 以 二氯甲烷N,N-二甲基乙酰胺 为溶剂, 反应 23.0h, 生成 2-(dimethyl(vinyl)silyl)-6-phenylhexanenitrile
    参考文献:
    名称:
    镍催化 α-氰基烷基亲电子试剂和氯硅烷的还原 C(sp3)−Si 交叉偶联
    摘要:
    报道了由 α-氰基和氯硅烷活化的烷基亲电试剂在镍/锌催化下的交叉亲电偶联。元素锌是该还原偶联过程中的化学计量还原剂。由此,可以从两种亲电反应物开始形成C(sp 3 )-Si键,而之前的方法依赖于碳亲核试剂和硅亲电试剂的组合,反之亦然。
    DOI:
    10.1002/anie.202107492
  • 作为产物:
    描述:
    苯戊醇sodium hypochlorite4-乙酰氨-2,2,6,6-四甲基哌啶-1-氧碳酸氢钠sodium hydrogensulfite 、 sodium bromide 作用下, 以 二氯甲烷乙酸乙酯 为溶剂, 反应 19.75h, 生成 2-羟基-6-苯基己腈
    参考文献:
    名称:
    在分子对接计算和分子动力学模拟的指导下,开发了一种有效的分泌型磷脂酶A2的2-氧酰胺抑制剂。
    摘要:
    抑制IIA组分泌的磷脂酶A2(GIIA sPLA2)已成为药物化学家的重要目标。先前我们已经表明,结合了2-氧酰胺功能的抑制剂可能会抑制人和小鼠GIIA sPLA2。在此,描述了使用已知的抑制剂7的结构通过分子对接计算来开发新的有效抑制剂的方法。新化合物的合成和生物学评估表明,基于(S)-缬氨酸GK241的长链2-氧代酰胺可提高活性(分别针对人和小鼠GIIA sPLA2的IC50 = 143nM和68nM)。此外,采用分子动力学模拟来阐明GK241的有效和选择性抑制活性。
    DOI:
    10.1016/j.bmc.2016.02.040
点击查看最新优质反应信息

文献信息

  • Comprehensive Analysis of Structure–Activity Relationships of α-Ketoheterocycles as <i>sn</i>-1-Diacylglycerol Lipase α Inhibitors
    作者:Freek J. Janssen、Marc P. Baggelaar、Jessica J. A. Hummel、Herman S. Overkleeft、Benjamin F. Cravatt、Dale L. Boger、Mario van der Stelt
    DOI:10.1021/acs.jmedchem.5b01627
    日期:2015.12.24
    Diacylglycerol lipase alpha (DAGL alpha) is responsible for the formation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system. DAGL alpha inhibitors are required to study the physiological mile of 2-AG. Previously, we identified the alpha-ketoheterocycles as potent and highly selective DAGL alpha inhibitors. Here, we present the first comprehensive structure activity relationship study Of alpha-ketohetero cycles as DAGL alpha inhibitors. Our findings indicate that the active site, of DAGL alpha is remarkably sensitive to the type of heterocyclic scaffold with oxazolo-4N-pridines as the most active framework We uncovered a fundamental substituent effect in which electron-withdrawing meta-oxazole substituents increased inhibitor potency. (C-6-C-9)-iacyl chains with a distal phenyl group proved to be the most potent inhibitors. The integrated SAR data was consistent with the proposed binding pose in a DAGL alpha homology model. Altogether, our results may guide the design of future DAGL alpha inhibitors as leads for molecular therapies to treat neuroinflammation, obesity, and related metabolic disorders.
  • PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS
    申请人:Universiteit Leiden
    公开号:EP3145935A1
    公开(公告)日:2017-03-29
  • COMPOUND
    申请人:Kokotos George
    公开号:US20110136879A1
    公开(公告)日:2011-06-09
    The invention provides compounds of formula (I) wherein X is O or S; R 1 is H, OH, SH, nitro, NH 2 , NHC 1-6 alkyl, N(C 1-6 alkyl) 2 , halo, haloC 1-6 alkyl, CN, C 1-6 -alkyl, OC 1-6 alkyl, C 1-6 alkylCOOH, C 1-6 alkylCOOC 1-6 alkyl, C 2-6 -alkenyl, C 3-10 cycloalkyl, C 6-10 aryl, C 1-6 alkylC 6-10 aryl, heterocyclyl, heteroaryl, CONH 2 , CONHC 1-6 alkyl, CON(C 1-6 alkyl) 2 , OCOC 1-6 alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R 2 is as defined for R 1 or R 1 and R 2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R 5 ; R 3 is H, halo (preferably fluoro), or CHal 3 (preferably CF 3 ), each R 5 is defined as for R 1 ; V 1 is a covalent bond or a C 1-20 alkyl group, or C 2-20 -mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C 1-6 alkyl), S, SO, or SO 2 ; M 1 is absent or is a C 5-10 cyclic group or a C 5-15 aromatic group; and R 4 is H, halo, OH, CN, nitro, NH 2 , NHC 1-6 alkyl, N(C 1-6 alkyl) 2 , haloC 1-6 alkyl, a C 1-20 alkyl group, or C 2-20 -mono or multiply unsaturated alkenyl group, said C 1-20 alkyl or C 2-20 alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C 1-6 alkyl), S, SO, or SO 2 ; with the proviso that the group V 1 M 1 R 4 as a whole provides at least 4 backbone atoms from the C(R 3 ) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.
  • [EN] PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS<br/>[FR] COMPOSÉS PHARMACEUTIQUEMENT ACTIFS À TITRE D'INHIBITEURS DE LIPASES DAG
    申请人:UNIV LEIDEN
    公开号:WO2016188972A1
    公开(公告)日:2016-12-01
    The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-a (alternative name: Snl-specific diacylglycerol hydrolase a; DAGL-a) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive compounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity, wherein X1 is -CH-, -CF- or -N-.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫